Company intelligence / Profile preview
Amgen
- Ownership
- Public · AMGN
- Employees
- ~28000
- Development stage
- Other
Overview
Amgen has over four decades of experience developing innovative medicines for serious illnesses. Its marketed portfolio includes leading biologics for cancer supportive care, autoimmune disorders, bone health, cardiovascular disease, and rare diseases. The company continues to advance a broad pipeline with numerous programs in mid-to-late clinical stages across oncology, inflammation, general medicine and rare diseases.
- Therapeutic areas
- Rare DiseasesEndocrinologyOncologyNephrologyImmunologyCardiovascular
- Modalities
- Recombinant proteins (e.g., erythropoietin, G-CSF)Monoclonal antibodies (mAbs)Small moleculesBiosimilars
- Industry
- Pharma
Drug pipeline
297 assets296 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $251.9B
- Total revenue
- $36.7B
- Enterprise value
- $295.3B
Beyond the preview
Go deeper on Amgen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amgen.